NAS:PGNX (USA) Also trade in: Germany UK

Progenics Pharmaceuticals Inc

$ 5.37 0.07 (1.32%)
Volume: 1,011,234 Avg Vol (1m): 811,905
Market Cap $: 463.83 Mil Enterprise Value $: 397.88 Mil
P/E (TTM): 0.00 P/B: 5.46
Earnings Power Value -15.28
Net Current Asset Value 0.44
Tangible Book 0.69
Projected FCF -2.44
Median P/S Value 2.43
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4.6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 2.51
Cash-To-Debt range over the past 10 years
Min: 1.68, Med: 9069.83, Max: 10000
Current: 2.51
1.68
10000
Equity-to-Asset 0.51
Equity-to-Asset range over the past 10 years
Min: 0.31, Med: 0.84, Max: 0.98
Current: 0.51
0.31
0.98
Debt-to-Equity 0.52
Debt-to-Equity range over the past 10 years
Min: -0.5, Med: 0.01, Max: 0.83
Current: 0.52
-0.5
0.83
Debt-to-EBITDA -0.83
Debt-to-EBITDA range over the past 10 years
Min: -0.94, Med: -0.91, Max: 4.67
Current: -0.83
-0.94
4.67
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.07
DISTRESS
GREY
SAFE
Beneish M-Score -2.38
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -304.15%
WACC 14.64%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -327.11
Operating Margin range over the past 10 years
Min: -878.82, Med: -283.01, Max: 17
Current: -327.11
-878.82
17
Net Margin % -436.57
Net Margin range over the past 10 years
Min: -876.82, Med: -342.65, Max: 15.56
Current: -436.57
-876.82
15.56
ROE % -86.30
ROE range over the past 10 years
Min: -87.75, Med: -43.77, Max: 16.86
Current: -86.3
-87.75
16.86
ROA % -45.65
ROA range over the past 10 years
Min: -79.08, Med: -28.17, Max: 14.53
Current: -45.65
-79.08
14.53
ROC (Joel Greenblatt) % -1241.05
ROC (Joel Greenblatt) range over the past 10 years
Min: -1520.63, Med: -930.37, Max: 303.97
Current: -1241.05
-1520.63
303.97
3-Year Total Revenue Growth Rate 21.70
3-Year Revenue Growth Rate range over the past 10 years
Min: -55.5, Med: -16.25, Max: 91.5
Current: 17.5
-55.5
91.5
3-Year Total EBITDA Growth Rate -8.50
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -27.3, Max: 28.8
Current: -4.5
0
28.8
3-Year EPS w/o NRI Growth Rate -15.80
N/A

» PGNX's 30-Y Financials

Financials (Next Earnings Date: 2019-07-31)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:PGNX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare SZSE:300381 SZSE:000518 HKSE:00775 NAS:CCXI BOM:540701 WAR:CLN XAMS:PHARM XKRX:083790 SZSE:300181 SZSE:300583 NAS:BYSI NAS:GLYC NAS:DERM ASX:MSB NAS:CTMX HKSE:01061 SHSE:603566 NAS:OBSV NAS:AKBA NAS:RVNC
Traded in other countries PGP.Germany 0KOA.UK
Address One World Trade Center, 47th Floor, Suite J, New York, NY, USA, 10007
Progenics Pharmaceuticals is an American biotechnology company. The company develops innovative medicines to treat cancer. Progenics Pharmaceuticals' portfolio includes AZEDRA (to treat malignant and/or recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Ratios

Current vs industry vs history
PB Ratio 5.46
PB Ratio range over the past 10 years
Min: 1.14, Med: 3.64, Max: 10.93
Current: 5.46
1.14
10.93
PS Ratio 25.92
PS Ratio range over the past 10 years
Min: 2, Med: 11.73, Max: 177.27
Current: 25.92
2
177.27
EV-to-EBIT -7.30
EV-to-EBIT range over the past 10 years
Min: -222.3, Med: -2.8, Max: 95
Current: -7.3
-222.3
95
EV-to-EBITDA -7.57
EV-to-EBITDA range over the past 10 years
Min: -483.1, Med: -3.1, Max: 81.2
Current: -7.57
-483.1
81.2
EV-to-Revenue 23.80
EV-to-Revenue range over the past 10 years
Min: 0.4, Med: 8.8, Max: 150.6
Current: 23.8
0.4
150.6
Current Ratio 4.81
Current Ratio range over the past 10 years
Min: 0.42, Med: 9.59, Max: 32.92
Current: 4.81
0.42
32.92
Quick Ratio 4.81
Quick Ratio range over the past 10 years
Min: 0.42, Med: 9.59, Max: 32.92
Current: 4.81
0.42
32.92
Days Sales Outstanding 90.87
Days Sales Outstanding range over the past 10 years
Min: 0.44, Med: 89.21, Max: 179.75
Current: 90.87
0.44
179.75

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -3.60
3-Year Share Buyback Rate range over the past 10 years
Min: -73.6, Med: -10.8, Max: -0.9
Current: -3.6
-73.6
-0.9

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 7.78
Price-to-Tangible-Book range over the past 10 years
Min: 1.22, Med: 5.39, Max: 31.48
Current: 7.78
1.22
31.48
Price-to-Median-PS-Value 2.21
Price-to-Median-PS-Value range over the past 10 years
Min: 0.2, Med: 1.13, Max: 11.22
Current: 2.21
0.2
11.22
Earnings Yield (Joel Greenblatt) % -13.71
Earnings Yield (Greenblatt) range over the past 10 years
Min: -305.9, Med: -15.4, Max: 10.2
Current: -13.71
-305.9
10.2

More Statistics

Revenue (TTM) (Mil) $ 16.71
EPS (TTM) $ -0.89
Beta 2.6
Volatility % 65.41
52-Week Range $ 3.62 - 9.42
Shares Outstanding (Mil) 86.37

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y